VRTX is plugging the rate of anemia discontinuations: 0.8%, 3.3%, and 0.6% for the ‘12+12’, ‘8+24’, and control arms, respectively. We know why they are doing this.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”